Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the Sponsor.
On 12 December 2016, orphan designation (EU/3/16/1798) was granted by the European Commission to Merck Serono Europe Limited, United Kingdom, for avelumab for the treatment of gastric cancer.
The sponsorship was transferred to Merck Europe B.V., The Netherlands, in June 2018.
|Disease / condition||
Treatment of gastric cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.